Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations
Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, according to an international Phase II trial led by The University of Texas MD Anderson Cancer Center.
The trial results, published today in the New England Journal of Medicine, led to approval of erdafitinib in April by the Food and...
Discovery shows how difficult-to-treat prostate cancer evades immune system
Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative...
New biomarker-guided strategy has potential for liver cancer treatment
A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing...
Joel Dahmen named MD Anderson's official PGA TOUR ambassador
The University of Texas MD Anderson Cancer Center, the official cancer center of the PGA TOUR, today announced its partnership with Joel Dahmen, PGA TOUR golf professional. Dahmen will serve as MD Anderson’s official PGA TOUR ambassador to educate the public on cancer prevention and to promote the institution’s mission to end cancer.
Dahmen is no stranger to the impact cancer can have on a family...
